Cargando...

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis

Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marziniak, Martin, Meuth, Sven
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2014
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177103/
https://ncbi.nlm.nih.gov/pubmed/25182864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-014-0149-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!